Executives Across Greif, Alpha Tau, Crawford, and Estée Lauder Sell Millions in Stock

Four senior executives at unrelated public companies disclosed insider stock sales in SEC Form 4 filings this week, spanning packaging maker Greif Inc. GEF, radiotherapy device maker Alpha Tau Medical DRTS, claims-management firm Crawford & Company, and cosmetics group Estée Lauder EL. The filings, covering transactions dated August 20 through August 24, 2026, show a mix of routine diversification and at least one sale executed outside any pre-arranged trading plan.

Insider sales attract scrutiny mainly because they reveal how executives are treating their own equity relative to public shareholders. Of the four, only Alpha Tau Medical's sale was confirmed as a pre-arranged Rule 10b5-1 plan transaction, which removes discretionary timing from the equation. Crawford & Company's sale was explicitly not covered by such a plan, meaning the executive chose when to sell. The trading-plan status of the Greif and Estée Lauder sales was not disclosed in the filings reviewed, so neither should be assumed routine or discretionary.

Greif's executive vice president and chief human resources officer, Bala Sathyanarayanan, sold 1,000 shares on August 24th for $109,670, reducing his direct stake to 7,549 shares . Alpha Tau Medical's chief financial officer, Raphi Levy, sold 2,871 shares on August 21st for $43,065 under the confirmed 10b5-1 plan, leaving him with 90,180 shares worth about $1.35 million . Crawford & Company's executive vice president, Andrew John Bart, sold 3,305 shares on August 24th for $44,155 in a sale that was not part of a 10b5-1 plan, retaining 86,395 shares valued at roughly $1.15 million . Estée Lauder's executive vice president and general counsel, Rashida Lande, sold 5,564 shares on August 21st for $553,896 . That sale was one leg of a same-day sequence that also included an option exercise and a separate stock grant: her direct holdings fell to zero immediately after the sale, before the grant brought her position back up to 11,129 shares.

None of the four filings disclose a stated reason for the sales, and the confirmed percentage reductions range from 3.09% at Alpha Tau to 3.68% at Crawford, both consistent with routine diversification rather than a wholesale exit. Because the sales are not uniformly plan-driven, investors should treat Crawford's discretionary sale and Estée Lauder's multi-leg transaction as distinct signals from Alpha Tau's scheduled disposal, rather than folding all four into a single insider-selling narrative. Any additional Form 4 filings from these executives in the coming weeks would be worth watching for confirmation of whether this is isolated activity or a developing pattern.

Related Stocks

• EL